Regeneron Pharmaceuticals, Inc.
Stabilized Formulations Containing Anti-IL-33 Antibodies
Last updated:
Abstract:
The present invention provides pharmaceutical formulations comprising an antibody that specifically binds to human interleukin-33 (hIL-33). The formulations may contain, in addition to an anti-IL-33 antibody, a buffer, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months and after being subjected to thermal and other physical stresses.
Status:
Application
Type:
Utility
Filling date:
20 Mar 2020
Issue date:
24 Sep 2020